Table 1.
Baseline characteristics according to baseline BMI (pooled data from FINCH 1–3)
| Characteristica | Baseline BMI (kg/m2) | |||
|---|---|---|---|---|
| Overall (N = 3452) | < 25 (n = 1332) | 25 to < 30 (n = 1102) | ≥ 30 (n = 1018) | |
| Duration of RA from diagnosis (years) | ||||
| n | 3452 | 1332 | 1102 | 1018 |
| Mean (SD) | 6.35 (7.82) | 6.23 (7.47) | 6.82 (8.64) | 6.00 (7.30) |
| Presence of RF | 2471 (71.6) | 1005 (75.5) | 797 (72.3) | 669 (65.7) |
| Presence of anti-CCP antibodies | 2564 (74.3) | 1067 (80.1) | 835 (75.8) | 662 (65.0) |
| Presence of both RF and anti-CCP antibodies | 2236 (64.8) | 915 (68.7) | 733 (66.5) | 588 (57.8) |
| Prior exposure to bDMARDs | 494 (14.3) | 132 (9.9) | 146 (13.2) | 216 (21.2) |
| Concurrent oral corticosteroids use | 1526 (44.2) | 597 (44.8) | 511 (46.4) | 418 (41.1) |
| Concurrent oral corticosteroid dose (mg/day) | ||||
| n | 1521 | 595 | 509 | 417 |
| Mean (SD) | 6.26 (2.64) | 6.00 (2.47) | 6.49 (2.86) | 6.33 (2.55) |
| Concurrent methotrexate use | 2122 (61.5) | 854 (64.1) | 669 (60.7) | 599 (58.8) |
| Concurrent methotrexate dose (mg/week) | ||||
| n | 2120 | 852 | 669 | 599 |
| Mean (SD) | 15.34 (4.86) | 14.64 (4.92) | 15.57 (4.69) | 16.09 (4.82) |
| Swollen joint count based on 66 joints | ||||
| n | 3451 | 1332 | 1101 | 1018 |
| Mean (SD) | 16.0 (9.4) | 15.6 (9.0) | 15.7 (8.7) | 17.0 (10.3) |
| Tender joint count based on 68 joints | ||||
| n | 3451 | 1332 | 1101 | 1018 |
| Mean (SD) | 25.3 (14.0) | 24.1 (13.6) | 25.3 (13.7) | 26.8 (14.6) |
| Swollen joint count based on 28 joints | ||||
| n | 3452 | 1332 | 1102 | 1018 |
| Mean (SD) | 11.3 (5.4) | 11.1 (5.4) | 11.2 (5.2) | 11.7 (5.7) |
| Tender joint count based on 28 joints | ||||
| n | 3452 | 1332 | 1102 | 1018 |
| Mean (SD) | 15.1 (6.6) | 14.5 (6.6) | 15.3 (6.4) | 15.6 (6.8) |
| HAQ-DI | ||||
| n | 3450 | 1331 | 1101 | 1018 |
| Mean (SD) | 1.588 (0.628) | 1.497 (0.655) | 1.624 (0.612) | 1.666 (0.593) |
| DAS28-CRP | ||||
| n | 3452 | 1332 | 1102 | 1018 |
| Mean (SD) | 5.75 (0.95) | 5.66 (0.98) | 5.77 (0.92) | 5.85 (0.93) |
| SF-36 physical component summary | ||||
| n | 3441 | 1327 | 1099 | 1015 |
| Mean (SD) | 33.09 (7.57) | 34.66 (7.73) | 32.58 (7.28) | 31.58 (7.28) |
| SF-36 mental component summary | ||||
| n | 3441 | 1327 | 1099 | 1015 |
| Mean (SD) | 43.95 (10.94) | 43.36 (10.91) | 44.42 (10.86) | 44.19 (11.04) |
| FACIT-F | ||||
| n | 3421 | 1320 | 1091 | 1010 |
| Mean (SD) | 27.06 (10.87) | 28.20 (10.91) | 27.48 (10.54) | 25.11 (10.91) |
| Patient’s pain assessment (mm) | ||||
| n | 3450 | 1331 | 1101 | 1018 |
| Mean (SD) | 65.5 (20.5) | 63.9 (20.8) | 66.2 (20.1) | 66.7 (20.4) |
| Patient’s global assessment of disease activity (mm) | ||||
| n | 3452 | 1332 | 1102 | 1018 |
| Mean (SD) | 66.7 (19.9) | 65.4 (20.1) | 67.5 (19.3) | 67.7 (20.0) |
| Physician’s global assessment of disease activity (mm) | ||||
| n | 3452 | 1332 | 1102 | 1018 |
| Mean (SD) | 66.3 (16.4) | 65.9 (16.7) | 66.8 (16.0) | 66.3 (16.6) |
| Simplified disease activity index | ||||
| n | 3452 | 1332 | 1102 | 1018 |
| Mean (SD) | 41.36 (12.93) | 40.52 (13.14) | 41.53 (12.40) | 42.29 (13.14) |
| Clinical disease activity index | ||||
| n | 3452 | 1332 | 1102 | 1018 |
| Mean (SD) | 39.68 (12.32) | 38.75 (12.35) | 39.86 (11.85) | 40.69 (12.70) |
| hsCRP (mg/l) | ||||
| n | 3452 | 1332 | 1102 | 1018 |
| Mean (SD) | 16.87 (23.13) | 17.66 (25.63) | 16.67 (22.83) | 16.04 (19.74) |
| hsCRP ≥ 6 mg/l | 2108 (61.1) | 770 (57.8) | 656 (59.5) | 682 (67.0) |
| Medical history of cardiovascular riskb | 1581 (45.8) | 401 (30.1) | 528 (47.9) | 652 (64.0) |
| Smoking status | ||||
| Current smoker | 482 (14.0) | 199 (14.9) | 162 (14.7) | 121 (11.9) |
| Former smoker | 477 (13.8) | 153 (11.5) | 149 (13.5) | 175 (17.2) |
| Non-smoker | 2493 (72.2) | 980 (73.6) | 791 (71.8) | 722 (70.9) |
| Alcohol use | 713 (20.7) | 295 (22.1) | 211 (19.1) | 207 (20.3) |
| Creatinine clearance (ml/min) | ||||
| n | 3452 | 1332 | 1102 | 1018 |
| Mean (SD) | 114.0 (39.0) | 97.2 (27.0) | 111.6 (32.5) | 138.6 (45.7) |
bDMARD biologic disease-modifying anti-rheumatic drug, BMI body mass index, CCP cyclic citrullinated peptide, DAS28-CRP Disease Activity Score-28 using C-reactive protein, FACIT-F Functional Assessment of Chronic Illness Therapy-Fatigue, HAQ-DI Health Assessment Questionnaire–Disability Index, hsCRP high-sensitivity C-reactive protein, RA rheumatoid arthritis, RF rheumatoid factor, SD standard deviation, SF-36 36-Item Short-Form Survey
aData are presented as n (%) unless stated otherwise
bDefined as: current or former smoking; first-degree relative with myocardial infarction/stroke before age 50 (family history); or a medical history of diabetes mellitus, peripheral vascular disease, hypertension, dyslipidemia, ischemic heart disease, ischemic central nervous system vascular disorders or extra-articular disease